Pharma’s post-pandemic launch performance problem: what’s the prognosis?
pharmaphorum
JUNE 29, 2022
However, this picture of recovery hides a less positive trend – non-COVID innovative launches from 2020 onwards, have, with certain exceptions, under-performed pre-pandemic benchmarks of launch sales performance in the major countries in the market – that is, the US, EU4+UK, China and Japan. The scope of the problem.
59 
Let's personalize your content